Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Intercept Pharmaceuticals, Inc. Common Stock Intraday Chart
|Intraday||Last 52 Weeks|
|High||$ 151.33||$ 314.88|
|Low||$ 146.475||$ 89.76|
The current last sale of $147.34 is 64.15% Higher thanthe 52 week low.
ETFs with ICPT as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|0%||BioShares Biotechnology Clinical Trials Fund (BBC)||-9.27 (-31.75%)|
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases. Our product candidates have the potential to treat orphan and more prevalent liver diseases for which there currently are limited therapeutic solutions. Our lead product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid, that selectively binds to and activates the farnesoid X receptor, or FXR, which we believe has broad liver-protective properties. OCA has been tested in five placebo-controlled clinical trials, including a Phase 3 clinical trial in patients with primary biliary cirrhosis, recently renamed primary biliary cholangitis, or PBC, and two Phase 2 clinical trials in patients with nonalcoholic fatty liver disease, or NAFLD, and nonalcoholic steatohepatitis, or NASH. ... More ...
Where does ICPT fit in the risk graph?
Nasdaq Official Price
|Annual EPS Est:||$-9.56|
|Quarterly EPS Est:||-3.58|